Browse by Journal Title

2024

Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models.
Pusch, F.F. and Dorado Garcia, H. and Xu, R. and Gürgen, D. and Bei, Y. and Brückner, L. and Röefzaad, C. and von Stebut, J. and Bardinet, V. and Chamorro Gonzalez, R. and Eggert, A. and Schulte, J.H. and Hundsdörfer, P. and Seifert, G. and Haase, K. and Schäfer, B.W. and Wachtel, M. and Kühl, A.A. and Ortiz, M.V. and Wengner, A.M. and Scheer, M. and Henssen, A.G.
Molecular Cancer Therapeutics 23 (4): 507-519. 2 April 2024

2016

ERK1 as a therapeutic target for dendritic cell vaccination against high-grade gliomas.
Ku, M.C. and Edes, I. and Bendix, I. and Pohlmann, A. and Waiczies, H. and Prozorovski, T. and Günther, M. and Martin, C. and Pagès, G. and Wolf, S.A. and Kettenmann, H. and Uckert, W. and Niendorf, T. and Waiczies, S.
Molecular Cancer Therapeutics 15 (8): 1975-1987. August 2016

CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M. and Yu, Y. and Milanovic, M. and Schönlein, M. and Rosenfeldt, M.T. and Dörr, J.R. and Kaufmann, A.M. and Dörken, B. and Schmitt, C.A.
Molecular Cancer Therapeutics 15 (5): 1074-1081. May 2016

Developing antagonists for the Met-HGF/SF protein-protein interaction using a fragment-based approach.
Winter, A. and Sigurdardottir, A.G. and DiCara, D. and Valenti, G. and Blundell, T.L. and Gherardi, E.
Molecular Cancer Therapeutics 15 (1): 3-14. January 2016

2010

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Brueckner, B. and Rius, M. and Rivera Markelova, M. and Fichtner, I. and Hals, P.A. and Sandvold, M.L. and Lyko, F.
Molecular Cancer Therapeutics 9 (5): 1256-1264. May 2010

2007

Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression.
Walther, W. and Arlt, F. and Fichtner, I. and Aumann, J. and Stein, U. and Schlag, P.M.
Molecular Cancer Therapeutics 6 (1): 236-243. January 2007

2006

Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
Hu, H. and Jiang, C. and Schuster, T. and Li, G.X. and Daniel, P.T. and Lue, J.
Molecular Cancer Therapeutics 5 : 1873-1882. July 2006

2005

Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.
Becker, M. and Sommer, A. and Kraetzschmar, J.R. and Seidel, H. and Pohlenz, H.D. and Fichtner, I.
Molecular Cancer Therapeutics 4 : 151-170. 1 January 2005

2002

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw, T.D. and Bibby, M.C. and Double, J.A. and Fichtner, I. and Cooper, P.A. and Alley, M.C. and Donohue, S. and Stinson, S.F. and Tomaszewjski, J.E. and Sausville, E.A. and Stevens, M.F.G.
Molecular Cancer Therapeutics 1 (4): 239-246. 1 February 2002